Silo Pharma, Inc. Files 8-K: Material Agreement & Equity Sales
Ticker: SILO · Form: 8-K · Filed: Jul 29, 2025 · CIK: 1514183
| Field | Detail |
|---|---|
| Company | Silo Pharma, Inc. (SILO) |
| Form Type | 8-K |
| Filed Date | Jul 29, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
Related Tickers: SILO
TL;DR
Silo Pharma (SILO) filed an 8-K on 7/29/25 detailing a material definitive agreement and unregistered equity sales.
AI Summary
On July 29, 2025, Silo Pharma, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. The filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate activity for Silo Pharma, Inc., including a new material agreement and equity transactions, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Silo Pharma, Inc. (company) — Registrant
- July 29, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 001-41512 (commission_file_number) — SEC File Number
- 677 N. Washington Blvd (address) — Business and Mail Address
FAQ
What is the nature of the material definitive agreement entered into by Silo Pharma, Inc. on July 29, 2025?
The filing indicates that Silo Pharma, Inc. entered into a material definitive agreement on July 29, 2025, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold by Silo Pharma, Inc. under the unregistered sales provision?
The filing mentions unregistered sales of equity securities, but the specific type and details of these securities are not detailed in the provided text.
What are the 'Other Events' reported by Silo Pharma, Inc. in this 8-K filing?
The filing lists 'Other Events' as a category of information, but the specific details of these events are not elaborated upon in the provided text.
What is the significance of Silo Pharma, Inc. filing financial statements and exhibits with this 8-K?
The inclusion of financial statements and exhibits suggests that the company is providing supporting financial documentation related to the events reported in the 8-K filing.
What was Silo Pharma, Inc.'s former company name prior to becoming Silo Pharma, Inc.?
Silo Pharma, Inc. was formerly known as Uppercut Brands, Inc. (name change date: 20190808), Point Capital, Inc. (name change date: 20130130), and Gold Swap Inc (name change date: 20110301).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 29, 2025 regarding Silo Pharma, Inc. (SILO).